The DOI matches its Crossref record.
Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy
Abstract
PURPOSE: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores generated from resected tumor tissue. We evaluated the prognostic usefulness of the score derived from biopsy specimens in men treated with radical prostatectomy. MATERIALS AND METHODS: We evaluated the cell cycle progression score in cohorts of patients from the Martini Clinic (283), Durham Veterans Affairs Medical Center (176) and Intermountain Healthcare (123). The score was derived from simulated biopsy (Martini Clinic) or diagnostic biopsy (Durham Veterans Affairs Medical Center and Intermountain Healthcare) and evaluated for an association with biochemical recurrence and metastatic disease. RESULTS: In all 3 cohorts the cell cycle progression score was associated with biochemical recurrence and metastatic disease. The association with biochemical recurrence remained significant after adjusting for other prognostic clinical variables. On combined analysis of all cohorts (total 582 patients) the score was a strong predictor of biochemical recurrence on univariate analysis (HR per score unit 1.60, 95% CI 1.35-1.90, p=2.4×10(-7)) and multivariate analysis (HR per score unit 1.47, 95% CI 1.23-1.76, p=4.7×10(-5)). Although there were few events (12), the cell cycle progression score was the strongest predictor of metastatic disease on univariate analysis (HR per score unit 5.35, 95% CI 2.89-9.92, p=2.1×10(-8)) and after adjusting for clinical variables (HR per score unit 4.19, 95% CI 2.08-8.45, p=8.2×10(-6)). CONCLUSIONS: The cell cycle progression score derived from a biopsy sample was associated with adverse outcomes after surgery. These results indicate that the score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Genomic Markers in Prostate Cancer Decision Making
Cucchiara, V., Cooperberg, M. R., Dall’Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.036 · Cited by 269
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 155
Self-citationGenomic classifiers and prognosis of localized prostate cancer: a systematic review
Boyer, M. J., Carpenter, D. J., Gingrich, J. R., Raman, S. R., Sirohi, D., Tabriz, A. A., Rompre-Broduer, A., Lunyera, J., Basher, F., Bitting, R. L., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00766-z · Cited by 22
Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer
Ingrosso, G., Alì, E., Marani, S., Saldi, S., Bellavita, R., & Aristei, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010065 · Cited by 9
Metadata
- Authors
- Bishoff, J. T., Freedland, S. J., Gerber, L., Tennstedt, P., Reid, J., Welbourn, W., Graefen, M., Sangale, Z., Tikishvili, E., Park, J., Younus, A., Gutin, A., Lanchbury, J. S., Sauter, G., Brawer, M., Stone, S., & Schlomm, T.
- Venue
- Journal of Urology
- Published
- 2014-08
- Volume
- 192
- Issue
- 2
- Pages
- 409-414
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2142044692
- Cited by
- 191
- References
- 0
- FWCI
- 24.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy. https://app.cochat.ai/papers/10.1016/j.juro.2014.02.003
- The paper
- Bishoff, J. T., Freedland, S. J., Gerber, L., Tennstedt, P., Reid, J., Welbourn, W., Graefen, M., Sangale, Z., Tikishvili, E., Park, J., Younus, A., Gutin, A., Lanchbury, J. S., Sauter, G., Brawer, M., Stone, S., & Schlomm, T. (2014). Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy. Journal of Urology. https://doi.org/10.1016/j.juro.2014.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.